Madam Chair, I thank the member for that question. It's a crucial one at this moment in time.
It actually speaks to the biomanufacturing and life sciences initiative that's being built coming out of the pandemic to strengthen our ability to create that pipeline and then sustain it in the long term so that ideas and research that find their initial formulation within the laboratory are well supported, are moved through the clinical trials networks and are scaled up appropriately. Then the IP would be maintained within Canada so that the trials are done here and the answers are used to benefit Canadians.
It is a fundamental investment that has been done to address exactly that question of ensuring that we maintain IP in Canada for innovation's purpose.